Gamma Delta T Cell Cancer Therapy Market Report 2026

The gamma delta t cell cancer therapy market size has grown rapidly in recent years. It will grow from $2.11 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 19%. The growth in the historic period can be attributed to limited availability of gamma delta t cell therapies, reliance on conventional chemotherapy and monoclonal antibodies, growing oncology patient population, increasing clinical trials in adoptive cell therapy, awareness of immunotherapy benefits.

The gamma delta t cell cancer therapy market size is expected to see rapid growth in the next few years. It will grow to $4.94 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to advancements in chimeric antigen receptor t cell therapies, expansion of cytokine and checkpoint inhibitor combination therapies, rising investment in personalized oncology, development of fully human monoclonal antibodies, integration of ai-driven patient monitoring and treatment optimization. Major trends in the forecast period include rising adoption of gamma delta t cell-based adoptive cell therapies, increasing development of combination immunotherapies, focus on targeting rare and refractory cancers, expansion of personalized and precision oncology programs, integration of immune checkpoint inhibition with cell therapy.

The increasing number of clinical trials is expected to drive the growth of the gamma delta T cell cancer therapy market in the coming years. Clinical trials are structured research studies conducted in humans to assess the safety, efficacy, and potential side effects of medical treatments, drugs, or interventions. The rise in clinical trials is driven by growing demand for novel therapies aimed at addressing unmet medical needs and improving patient outcomes. These trials advance gamma delta T cell cancer therapy by validating safety and efficacy, accelerating regulatory approvals, and enabling optimized treatment protocols. They also improve therapeutic outcomes by generating essential data that supports innovation and broader clinical adoption. For example, according to a report by the Association of the British Pharmaceutical Industry (ABPI) in December 2024, the total number of industry-sponsored clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. This growth in clinical trials is therefore supporting the expansion of the gamma delta T cell cancer therapy market.

Key companies in the gamma delta T cell cancer therapy market are focusing on innovative solutions, such as gamma delta (γδ) T cell engager (TCE) platforms, to enhance efficacy, improve targeting, and reduce off-tumor toxicity. γδ TCE platforms are engineered immunotherapies designed to redirect and activate γδ T cells to specifically recognize and kill cancer cells by bridging them with tumor-associated antigens. For instance, in March 2025, IN8bio Inc., a US-based biotechnology firm, launched the INB 600, a next-generation γδ TCE platform targeting both cancer and autoimmune diseases. Its lead candidate, INB 619, specifically targets CD19 and demonstrated the ability to expand γδ T cells by up to 450 times in preclinical studies, resulting in significant B-cell depletion. This platform leverages the natural tumor-targeting properties of gamma delta T cells and combines them with engineered engagers to boost their cancer-killing activity. The TCE platform aims to overcome limitations of conventional immunotherapies by improving specificity, reducing systemic side effects, and expanding the range of treatable cancers.

In October 2023, Clade Therapeutics Inc., a US-based biotechnology company, acquired Gadeta B.V. for an undisclosed amount. Through this acquisition, Clade Therapeutics seeks to enhance its platform by integrating Gadeta’s gamma delta TCR technology to develop off-the-shelf, stem cell-derived T cell therapies with universal targeting capabilities for solid tumors. Gadeta B.V., based in the Netherlands, specializes in gamma delta (γδ) T cell cancer therapies.

Major companies operating in the gamma delta t cell cancer therapy market are IN8bio Inc., American Gene Technologies International Inc., Adicet Bio Inc., LAVA Therapeutics N.V., Acepodia Inc., TC BioPharm (Holdings) plc, Century Therapeutics Inc., CytoMed Therapeutics Ltd., Appia Bio Inc., ImCheck Therapeutics S.A.S., JY BioMed Inc., Luminary Therapeutics Inc.

North America was the largest region in the gamma delta T cell cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gamma delta t cell cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gamma delta t cell cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the gamma delta t cell cancer therapy market by increasing costs for imported biologics, cell culture media, and advanced immunotherapy reagents. Segments like adoptive cell therapies and combination immunotherapies are most affected, with North America and Europe being heavily dependent on imports. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs are promoting local manufacturing, boosting domestic research capabilities, and encouraging innovation in cost-effective immunotherapy solutions.

The gamma delta t cell cancer therapy market research report is one of a series of new reports that provides gamma delta t cell cancer therapy market statistics, including gamma delta t cell cancer therapy industry global market size, regional shares, competitors with a gamma delta t cell cancer therapy market share, detailed gamma delta t cell cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gamma delta t cell cancer therapy industry. This gamma delta t cell cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gamma delta T cell cancer therapy is an emerging type of immunotherapy that leverages the unique characteristics of gamma delta T cells to identify and eliminate cancer cells without requiring antigen presentation by major histocompatibility complex (MHC) molecules. The primary aim of this therapy is to utilize their innate ability to detect and destroy tumor cells, thereby boosting the body’s immune response against cancer.

The main types of gamma delta T cell cancer therapy include adoptive cell therapy, cytokine therapy, monoclonal antibodies, and combination therapies. Adoptive cell therapy involves the transfer of immune cells that have been activated or engineered outside the body to enhance their ability to target and destroy disease cells. This therapy is applied to various cancer types, including leukemia, lymphoma, solid tumors, and certain rare cancers, and is used across different cancer stages, such as early stage, advanced stage, and relapsed or refractory cases. Its mechanisms of action include T cell activation, inhibition of the tumor microenvironment, targeting of tumor antigens, and enhancement of immune checkpoint inhibition. The therapy serves a range of end users, including hospitals, specialized clinics, research institutions, and pharmaceutical companies.

The gamma delta T cell cancer therapy market consists of revenues earned by entities by providing services such as research and development of gamma delta T cell-based therapies, clinical trial support, immunotherapy development, patient-specific T cell engineering, and commercialization of targeted cancer treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The gamma delta T cell cancer therapy market also includes sales of gamma delta T cell therapy drugs, adoptive cell transfer kits, cell culture media and reagents, gene editing tools, and cryopreservation equipment. Values in this market are ‘factory gate’ values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.